Jazz Pharmaceuticals vs Royalty Pharma
JAZZ and RPRX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How JAZZ and RPRX compare
Royalty Pharma is the larger company, worth 2.5 times as much as Jazz Pharmaceuticals ($39.5B against $15.6B).
On earnings, Royalty Pharma is cheaper: it trades at 39.0× trailing earnings, against 78.4× for Jazz Pharmaceuticals.
Jazz Pharmaceuticals grew revenue faster over the last twelve months (13.5% versus 10.0% for Royalty Pharma).
Royalty Pharma keeps more of each dollar of sales as profit, with a net margin of 32.1% compared with 4.4% at Jazz Pharmaceuticals.
Royalty Pharma pays a dividend yielding 1.4%; Jazz Pharmaceuticals does not pay one.
Royalty Pharma scores higher on the StockData Score (8 against 7 for Jazz Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | JAZZ | RPRX |
|---|---|---|
| Size and price | ||
| Market cap | $15.6B | $39.5B |
| Share price | $240.71 | $68.68 |
| Change, 1 year | 70.6% | 75.4% |
| Change, 5 years | 94.0% | 64.0% |
| Beta (5Y) | 0.20 | 0.04 |
| Employees | 2,890 | 100 |
| StockData Score | ||
| Total score | 7 | 8 (better) |
| Valuation score | 0 | 0 |
| Growth score | 2 | 2 |
| Performance score | 3 (better) | 2 |
| Health score | 2 | 2 |
| Dividend score | 0 | 2 (better) |
| Valuation | ||
| P/E | 78.4× | 39.0× (better) |
| P/S | 3.3× (better) | 15.6× |
| P/B | 3.7× | – |
| EV/EBITDA | 43.1× | 33.5× (better) |
| P/FCF | 9.6× | – |
| PEG | – | 0.24 |
| FCF yield | 10.4% | – |
| Fair value | $108.40 | $45.76 |
| Margin of safety | −122% | −50.1% (better) |
| Growth | ||
| Revenue growth (TTM) | 13.5% (better) | 10.0% |
| Revenue growth, 5Y average | 12.5% (better) | 2.3% |
| Net income growth (TTM) | – | −20.4% |
| EPS growth (TTM) | – | −19.3% |
| EPS growth, 5Y average | – | 6.2% |
| Profitability | ||
| Operating margin | 9.0% | 59.6% (better) |
| Net margin | 4.4% | 32.1% (better) |
| FCF margin | 34.4% | – |
| Return on equity | 5.1% | – |
| Return on invested capital | 4.5% | – |
| Financial health | ||
| Debt / equity | 1.33 | – |
| Net debt / EBITDA | 6.37 | 5.37 (better) |
| Interest coverage | – | 4.2× |
| Current ratio | 1.82 | 2.80 (better) |
| Altman Z-score | 1.97 | 2.98 (better) |
| Piotroski F-score | 4 | 5 (better) |
| Dividends and buybacks | ||
| Dividend yield | – | 1.4% |
| Buyback yield | – | 0.81% |
| Shareholder yield | 0.00% | 2.2% (better) |
| Ownership | ||
| Held by institutions | 99.2% | 63.8% |
| Held by insiders | 3.4% | 22.6% |
| Insider net buying, 12 months | −$67.1M (better) | −$82.2M |
| Superinvestors holding | 1 | 2 (better) |
| Short interest, % of float | 9.3% | 2.9% |
Go deeper
- JAZZ stock overview
- JAZZ income statement
- JAZZ valuation and score
- RPRX stock overview
- RPRX income statement
- RPRX valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.